Johnson & Johnson $JNJ Stake Lifted by First Pacific Financial

First Pacific Financial increased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 1,139.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,133 shares of the company's stock after acquiring an additional 17,589 shares during the period. First Pacific Financial's holdings in Johnson & Johnson were worth $2,923,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC boosted its holdings in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the first quarter worth approximately $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the first quarter worth approximately $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the first quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the first quarter worth approximately $52,000. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $185.98 on Friday. The company's fifty day moving average is $175.78 and its 200-day moving average is $162.66. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $186.59. The firm has a market cap of $447.91 billion, a price-to-earnings ratio of 19.89, a price-to-earnings-growth ratio of 2.37 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the business posted $2.82 EPS. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson's dividend payout ratio is 55.61%.

Analysts Set New Price Targets

A number of analysts recently weighed in on JNJ shares. Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Bank of America upped their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a research report on Friday, September 19th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $181.40.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.